Standpoint Research Starts Kite Pharma (KITE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St edges higher as investors juggle earnings, Mideast risks and tariffs
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil down more than 4% on profit taking, report of China-backed push to end US-Iran fighting
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Kite Pharma (KITE) Patient Death Confirmed Non-Issue, Stifel Notes; Meanwhile Tumors 'Melting Away'
August 17, 2015 11:13 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $83 price target on Kite Pharma (NASDAQ: KITE) after the company confirmed a patient died after receiving KTE019 treatment in the Phase I portion of the ongoing DLBCL trial. The death was ruled not related to KTE019 by the investigator.... More
Kite Pharma (KITE) Bullish Stance Reiterated at Mizuho on KTE-C19 Update
August 17, 2015 8:55 AM EDTMizuho Securities analyst Peter Lawson reiterated his Outperform rating and $90 price target on Kite Pharma (NASDAQ: KITE) after the company announced it will host a conference call to discuss KTE-C19 Phase 1 data with news that the patient death is untreated to the drug.
Lawson commented, "KITE will host a conference call today at... More
Kite Pharma's (KITE) KTE-C19 Trial on Track to Advance to Pivotal Phase 2
August 17, 2015 8:01 AM EDTKite Pharma, Inc. (Kite) (Nasdaq: KITE) today provided an update from the Company's ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma (NHL) who have failed prior chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.
In May, Kite announced that the first patient was treated with KTE-C19 in... More
